welbournes

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (29/09/2023) announced the following final list of price concessions for September 2023: Drug Pack size Price concession Atorvastatin 80mg tablets 28 £5.32 Brimonidine 0.2% eye drops 5 £3.20 [...]

The post September 2023 Price Concessions Final Update appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Azelaic acid (Skinoren®) 20% cream. MSN/2023/090 Tier 2 – medium impact Date of issue 27th September 2023 Azelaic acid (Skinoren®) 20% cream is out of stock until early November 2023. Azelaic acid (Finacea®) 15% gel remains available but cannot support an [...]

The post Medicine Supply Notification: Azelaic acid (Skinoren®) 20% cream appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Disopyramide (Rythmodan®)100mg capsules. MSN/2023/091 Tier 2 – medium impact Date of issue 27th September 2023 Disopyramide (Rythmodan®)100mg capsules are out of stock until late October 2023. Disopyramide (Rythmodan®) 250mg prolonged release tablets are out of stock until mid-December 2023 but parallel [...]

The post Medicine Supply Notification: Disopyramide (Rythmodan®)100mg capsules appeared first on Community Pharmacy England.

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (27/09/2023) announced the following list of price concessions for September 2023: Drug Pack size Price concession Atomoxetine 10mg capsules 28 £44.45 Atomoxetine 18mg capsules 28 £42.95 Atomoxetine 25mg [...]

The post September 2023 Price Concessions 2nd Update appeared first on Community Pharmacy England.

National Patient Safety Alert: Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets. National Patient Safety Alert Reference Number: NatPSA/2023/011/DHSC Date issued: 27th September 2023 Brief description of the problem There are supply disruptions affecting various strengths of the following medications which are licensed for the treatment of attention deficit hyperactivity [...]

The post National Patient Safety Alert: Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets. appeared first on Community Pharmacy England.